ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,303.27
      0.12%
      US Tech 100
      18,062.00
      -0.10%
      Dow Jones
      40,003.59
      0.34%
      Brent Oil
      83.76
      0.00%
      Bitcoin
      66,969.54
      0.04%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Bolt Biotherapeutics Inc (BOLT)

      7. Bolt Biotherapeutics Inc (BOLT) News

      BOLT

      Bolt Biotherapeutics (BOLT)

      Bolt Biotherapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:BOLT
      DateTimeSourceHeadlineSymbolCompany
      05/15/20245:43PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
      05/14/20244:14PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
      05/14/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
      05/14/20244:05PMGlobeNewswire Inc.Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership TeamNASDAQ:BOLTBolt Biotherapeutics Inc
      03/21/20244:05PMGlobeNewswire Inc.Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
      03/06/20241:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
      03/06/20241:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
      02/27/20247:00AMGlobeNewswire Inc.Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:BOLTBolt Biotherapeutics Inc
      02/12/20249:41PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BOLTBolt Biotherapeutics Inc
      02/06/20241:09PMEdgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
      12/21/20237:30AMGlobeNewswire Inc.Pacira Appoints Frank D. Lee as Chief Executive OfficerNASDAQ:BOLTBolt Biotherapeutics Inc
      12/13/20231:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
      12/05/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®NASDAQ:BOLTBolt Biotherapeutics Inc
      11/09/20234:10PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
      11/09/20234:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
      11/09/20234:05PMGlobeNewswire Inc.Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
      11/07/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceNASDAQ:BOLTBolt Biotherapeutics Inc
      10/23/202310:30AMGlobeNewswire Inc.Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 CongressNASDAQ:BOLTBolt Biotherapeutics Inc
      10/18/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual MeetingNASDAQ:BOLTBolt Biotherapeutics Inc
      10/17/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced CancersNASDAQ:BOLTBolt Biotherapeutics Inc
      10/16/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023NASDAQ:BOLTBolt Biotherapeutics Inc
      09/28/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric CancersNASDAQ:BOLTBolt Biotherapeutics Inc
      09/12/20238:05AMGlobeNewswire Inc.Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042NASDAQ:BOLTBolt Biotherapeutics Inc
      09/05/20234:15PMGlobeNewswire Inc.Bolt Biotherapeutics to Participate in September Investor ConferencesNASDAQ:BOLTBolt Biotherapeutics Inc
      08/07/20234:10PMGlobeNewswire Inc.Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
      08/07/20234:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
      08/07/20234:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
      08/03/20237:30AMGlobeNewswire Inc.Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive CancerNASDAQ:BOLTBolt Biotherapeutics Inc
      07/31/20235:27PMGlobeNewswire Inc.Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023NASDAQ:BOLTBolt Biotherapeutics Inc
      06/14/20235:22PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BOLTBolt Biotherapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:BOLT